<DOC>
	<DOC>NCT01147237</DOC>
	<brief_summary>The utilization of everolimus-eluting coronary stents in a coronary artery diseases is effective in reducing both repeat revascularization and major adverse cardiac events within two year follow-up. To evaluate the procedural, short and long term clinical outcomes of multiple everolimus-eluting coronary stent implantation in long (&gt;30mm) coronary lesions.</brief_summary>
	<brief_title>Xience/Promus for Long Coronary Lesion Registry</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1. Age â‰¥20 years and are able to undergo CABG 2. Females who are not pregnant 3. Patients who present with angina symptoms or myocardial ischemia 4. Patients available for postprocedural observation and coronary angiography at 24 months 5. Patients who have signed patient informed consent 6. Lesion length is more than 30mm 7. De novo lesion or nonstented restenosed lesion 1. Patients contraindicated for antiplatelet therapy or anticoagulant therapy 2. Patients with significant allergic reaction to contrast medium 3. Chronic total occlusion 4. Lesion with TIMI0 5. Patients with chronic renal failure (SCr&gt;3.0mg/dl)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>